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ABSTRACT 
 
Impacts of Maternal Obesity on Metabolic Profiles in Postpartum Ewes. (August 2010)  
Jason Ray McKnight, B.S., Sam Houston State University 
Chair of Advisory Committee: Dr. Guoyao Wu 
 
 This study determined the effects of gestational obesity on the long-term 
metabolic status of the mother and if obesity management during or after pregnancy 
could attenuate these effects.  At 120 days prior to estrus, 8 ewes received 100% of NRC 
nutrient requirements (control group) and 24 ewes had free access to feed (obesity 
induction).  Beginning on day 42 of gestation, 8 obese ewes were restricted to 65% of 
NRC nutrient requirements. Following parturition, controls and all but one group of 
obese ewes were fed 100% of NRC nutrient requirements.  At postpartum days (PPD) 1 
and 150, glucose tolerance tests were administered to ewes. At both PPD1 and PPD150, 
obesity resulted in insulin resistance, impairment of whole-body glucose utilization, 
increased levels of circulating leptin, and altered profiles of amino acids in plasma; 
however, these effects were diminished in ewes receiving obesity management during or 
after gestation.  Additionally at PPD150, obesity increased the circulating levels of 
ammonia and urea in ewes, which was prevented by realimentation to 100% NRC 
requirements.  These results indicate that weight reduction in obese dams during 
pregnancy or after parturition can beneficially ameliorate the adverse effects of 
gestational obesity on the mother.   
  
iv
ACKNOWLEDGEMENTS 
 
I would first like to thank my parents for their support and guidance throughout 
my life. They have always been supportive of the life decisions I have made, and of the 
goals I have set for myself. They are always there when I need someone to confide in, 
and always helpful in their comments and suggestions. I am truly appreciative of all that 
they have done, and without them, many of my aspirations would not have been a 
success. 
I would next like to thank my advisor, Dr. Guoyao Wu, for sharing his 
knowledge, guidance, and trust throughout the course of my graduate career. Without his 
invaluable input, completion of this research would not have been possible. Dr. Wu is an 
excellent role model, advisor, and scientist, and the care and compassion he shows for 
his research and graduate students will have a profound impact on me throughout my 
life. I am deeply grateful for his willingness to help me in any way needed, and for 
teaching me the methods and knowledge necessary to conduct quality research.  
I would also like to thank all other graduate advisors, students, and technicians 
who helped in this work. I am very thankful for the assistance that Dr. Carey Satterfield 
offered throughout the course of this research, especially during the animal work and 
discussion of results. I would also like to thank Drs. Tom Spencer and Fuller Bazer for 
their help in manuscript clarification and preparation, and for their helpful suggestions. 
Finally, I would like to thank members and technicians of Dr. Wu’s lab and Sorin Greff 
for all the assistance they provided throughout the course of this research.  
  
v
TABLE OF CONTENTS 
 
              Page 
ABSTRACT ..............................................................................................................  iii 
ACKNOWLEDGEMENTS ......................................................................................  iv 
TABLE OF CONTENTS ..........................................................................................  v 
LIST OF FIGURES ...................................................................................................  vi 
LIST OF TABLES ....................................................................................................  vii 
  CHAPTER 
 I INTRODUCTION AND LITERATURE REVIEW ............................  1 
   
  The obesity epidemic ......................................................................    1 
  Weight gain during pregnancy .......................................................    3 
  Maternal complications of gestational obesity ...............................    6 
  Fetal and neonatal complications ...................................................  12 
  Obesity management during pregnancy .........................................  14 
  Summary and objectives .................................................................  19 
  Hypothesis ......................................................................................  19 
 
    II IMPACTS OF MATERNAL OBESITY ON METABOLIC  
  PROFILES IN POSTPARTUM EWES  ..............................................  21 
 
   Materials and methods ....................................................................  22 
   Results ............................................................................................  25 
   Discussion .......................................................................................  36 
III SUMMARY AND DIRECTION OF FUTURE RESEARCH .............      41 
           
REFERENCES ..........................................................................................................  42 
VITA ..........................................................................................................................  54 
  
vi
LIST OF FIGURES 
 
                                                                                                                                       Page 
 
Figure 1 Experimental Design  ................................................................................  23 
 
  
vii
LIST OF TABLES 
 
                                                                                                                                  Page 
Table 1 Concentrations of leptin, ammonia, urea, and non-esterified  
  fatty acids (NEFA) in plasma of ewes on PPD1 and PPD150 ..................  26 
 
Table 2 Concentrations of insulin in plasma of ewes on PPD1 and PPD150 ........  28 
 
Table 3 Concentrations of glucose in plasma of ewes on PPD1 and PPD150 .......  31 
Table 4 Kinetics of glucose in plasma of ewes on PPD1 and PPD150 ..................  32 
Table 5 Concentrations of amino acids in plasma of ewes on PPD1 at  
   0 and 120 min after i.v. administration of glucose ....................................  33 
 
Table 6 Concentrations of amino acids in plasma of ewes on PPD150 at  
   0 and 120 min after i.v. administration of glucose ....................................  34 
 
  
1
CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
The obesity epidemic 
The human conditions of being overweight and/or obese result from abnormal or 
excessive white fat accumulation in the body.  The World Health Organization (WHO 
2009) and the National Institutes of Health (NIH 1998) have defined overweight as a 
body mass index (BMI, kg/m2) of 25 to 29.9, and obesity as a BMI of 30 or greater. 
Further, obesity is characterized into 3 classes by BMI: Class I (30-34.9), Class II (35-
39.9), and Class III (greater than 40).  Over the past few decades, obesity has become a 
troubling pandemic in developed nations and some developing countries (Abelson and 
Kennedy 2004; CDC 2009).  In 2005, the WHO estimated that nearly 1.6 billion adults 
worldwide are overweight and at least 400 million are obese. In the United States alone, 
35% of adults are obese, and approximately two-thirds of the population is overweight 
(Flegal et al. 2010). Similarly, in Australia, 16% of the adult population is classified as 
obese, while 49% are classified as overweight (Schrauwers and Dekker 2009).  The 
obesity epidemic is not bound by societal factors, as adults and children from all groups 
of society are affected (CDC 2009).  Associated with obesity are a number of other 
health problems, such as insulin resistance, type II diabetes, atherosclerosis, stroke, 
hypertension, and some types of cancer (including colon and breast cancers) (Pi-Sunyer 
2003). 
____________ 
This thesis follows the style of Amino Acids. 
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As a result, obesity is claiming an increasing number of lives, and is a significant 
burden on the healthcare systems of the world. In the United States alone, approximately 
300,000 people die annually due to obesity related diseases, and 6-8% of health care 
expenditures can be attributed to obesity. Indeed, the WHO (2000) has declared that 
obesity is now so common that it is replacing the more traditional public healthcare 
concerns, including under-nutrition and infectious disease, as one of the most significant 
contributors to poor health. 
 The adverse effects of obesity may be more severe for women than for men 
(CDC 2009). For example, obesity is associated with developing asthma in women, but 
not in men (Beckett et al. 2001). Further, women are more likely to be obese than men, 
as 34% of women are obese compared to 28% of men (Flegal et al. 2010). Also, women 
are twice as likely as men to experience a major weight gain over a 10-year period. 
Women aged 25 to 34 have the greatest risk of major weight gain as compared to either 
men of the same ages or older women (Williamson et al. 1990).  Between 1980 and 
2004, the prevalence of obesity in women has doubled from 16.5% to around 33.2% 
(Flegal et al. 1998; Hedley et al. 2004).  
Women have two periods throughout their life in which they are extremely 
susceptible to high weight gains: pregnancy and menopause. This is probably due to 
multiple factors such as changes in hormones, physical activity, and mood. Race also 
seems to play a role in female obesity, as it has been determined that the problem of 
obesity is greatest in non-Hispanic black women (48.8%), as compared with Mexican-
American (38.9%) and non-Hispanic white women (31.3%), according to the Centers for 
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Disease Control and Prevention (CDC 2009). Of particular interest is the vast number of 
women of reproductive age who  are now becoming overweight (57%) or obese (30%) 
in the U.S. (CDC 2009), compared with the previous values of 16.5-33.2% for the 
reported prevalence of obesity (Abrams and Laros 1986; Naeye 1990; Taffel et al. 1993; 
Siega-Riz et al. 1994; Cogswell et al. 1995). This is particularly troubling, because 
pregnancy alone is a time of great stress on the body. Coupled with excess adipose 
tissue, the time during gestation could cause serious health consequences to the mother 
and the fetus.   
Weight gain during pregnancy 
Gestational weight gain is normally credited to increases in both lean and fat tissues of 
the mother and fetus as well as to the retention of amniotic fluid (Institute of Medicine 
1990). Smooth, progressive weight gain generally represents healthy fetal growth, 
whereas inconsistently high weight gain is primarily indicative of excess fat deposition 
in the mother. Gaining too much weight during pregnancy can be attributed to unhealthy 
eating and inadequate physical activity. Some of the maternal characteristics associated 
with an increased risk in low gestational weight gain can occur in combination, such as 
low family income, race, young age, unmarried status, and low educational levels 
(Institute of Medicine 1990).   
Pregnancy outcomes based on the amount of gestational weight gain are well 
studied, and over time, the ideal weight gain during pregnancy has been occasionally 
questioned and revised. In the past, gestational weight gain guidelines were restrictive 
due to concerns about gestational hypertensive disorders, labor and delivery 
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complications, and weight retention after parturition (Kiel et al. 2007; Schieve et al. 
1998). More recent updates have focused on preventing low birth-weight infants, and the 
current guidelines provide weight gain ranges depending on pre-pregnancy BMI. These 
guidelines were recommended by the US National Academy of Sciences Institute of 
Medicine (IOM 1990) to decrease the prevalence of low birth-weight infants and prevent 
conditions such as macrosomia, caesarean delivery, and postpartum weight retention 
associated with gaining too much weight during gestation (Rode et al. 2007; Shaikh et 
al. 2009). These recommendations were put in place to optimize chances of delivering an 
infant with a birth-weight between 3 and 4 kg. Current recommendations set forth by the 
IOM are a weight gain of 11.2 to 15.9 kg for women with a normal BMI, 6.8 to 11.2 kg 
for overweight women, and at least 6.8 kg for obese women (IOM 1990). After 
establishing the IOM recommendations with cutoff limits for each pre-pregnancy BMI 
class, current research has largely focused on testing the significant association of these 
guidelines to important clinical outcomes (Cedergren 2007). The majority of these 
studies found that weight gains within the IOM’s ranges were coupled to a better 
pregnancy outcome than weight gains outside these ranges (Abrams et al. 2000; Siega-
Riz et al. 1994; Cogswell et al. 1995; Stotland et al. 2006; Hedderson et al. 2006).  
One issue with the current IOM guidelines is that there is no upper limit on how 
much weight an obese woman should gain during pregnancy, only advising that they 
should gain at least 6.8 kg. Further, since obesity has now been classified into Class I, 
Class II, and Class III by the CDC and NIH, many researchers feel that improved weight 
gain guidelines should distinguish between the different levels of obesity (Kiel et al. 
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2007). Also called into question is the IOM’s definition of a “good pregnancy outcome”. 
These parameters are largely subjective and include birth weight, preterm delivery, 
Apgar scores, cesarean delivery, and labor complications. Indeed, the broad weight gain 
ranges resulting in good pregnancy outcomes is illustrated by results of a study from 
California where only 40% of women with good pregnancy outcomes had weight gains 
within the acceptable IOM limits. Additionally, there have been discussions about 
whether current IOM guidelines for weight gain are too high and contributing to the 
ongoing obesity epidemic (Feng and Naylor 1998). Moreover, the IOM weight gain 
guidelines are intended for women carrying one fetus. In women carrying multiple 
fetuses, weight gains appear to be greater by an amount larger than that accounted for by 
the weight of the additional fetus and support tissues, and so this should not be taken by 
healthcare providers as an instance where the pregnant woman is gaining excess weight.  
Finally, the weight gain guidelines set forth by the IOM were compiled from data 
looking largely into industrialized nations as well as mainly white populations (IOM). 
Therefore, weight gains for citizens in developing countries as well as non-whites may 
be different, as the conclusions and recommendations in the IOM report relate only to 
healthy women in the United States.  
Gaining too much weight during gestation has been shown in numerous studies 
to cause multiple problems in the both the mother and fetus/infant such as gestational 
diabetes, failed induction of labor, lacerations, instrumental delivery, macrosomia, 
postpartum weight retention, and others (DeVader et al. 2007). A dangerous trend is that 
a high percentage of mothers gain more weight than the IOM recommendation during 
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gestation. DeVader et al. (2007) found that more than 60% of the 94,696 women 
surveyed gained more than recommended in the IOM guidelines. Further, more than 
42% of mothers gained over 16 kg.  This is especially problematic since approximately 
one half of pregnant women beginning their pregnancy as either overweight or obese 
(CDC 2009), and obesity along with excess gestational weight gain can compound 
problems. Kiel et al. (2007) reported that 46% of obese women gained more than 11.3 
kg throughout gestation. Another study found that greater than 70% of obese women 
gained more than the recommended amount of weight for obese pregnant women, and 
21% gained greater than 16 kg, which would be considered excessive for even women of 
normal pre-pregnancy weight (Vesco et al. 2009). Further, Butte et al. (2004) found that 
overweight and obese pregnant women have a net accrual of fat mass equal to about 8.4 
kg, as opposed to 5.3 kg in women with a low BMI and 4.6 kg in those with a normal 
BMI. Also, the increases in fat mass seems to be centralized in the intra-abdominal area 
(Kinoshita and Itoh 2006), which may be of metabolic significance because fat deposited 
in this area is  more highly correlated with disease later in life than white fat in other 
anatomical sites. Therefore, great care needs to be taken to make sure that all women, 
regardless of BMI,  have weight gains in pregnancy closely monitored, but also that 
intervention  be employed in obese women to ensure a minimal gestational weight gain.  
Maternal complications of gestational obesity 
Excess weight increases the risk of glucose intolerance, a pre-diabetic state of 
dysglycemia associated with insulin resistance. Even in moderately overweight subjects, 
the occurrence of gestational diabetes mellitus (GDM) is 1.8 to 6.5 times greater than in 
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normal-weight subjects, while the incidence in obese subjects is 1.4-20 times higher 
(Galtier-Dereure et al. 2000). Pregnancy is already a time of insulin resistance in the 
mother, which may be necessary to allow an adequate nutrient supply and energy source 
for the developing fetus. Insulin resistance normally increases 50-60% over the course of 
a normal pregnancy. GDM is the result of an imbalance between pregnancy-induced 
insulin resistance, which is exacerbated by weight excess and inadequate compensatory 
hyperinsulinism.  Excess adipose tissue is a source of inflammatory cytokines and other 
metabolically active chemical mediators, such that obesity can be characterized by a 
state of low-grade chronic inflammation (Retnakaran et al. 2003). Obese pregnant 
women have a higher concentration of C-reactive protein and higher fasting and 
postprandial insulin concentrations than non-obese women. All of these factors lead to 
an increase in GDM with increasing adipose tissue such that the risk of GDM has been 
shown to increase with rising maternal BMI; overweight women have relative risk of 
1.7, while obese women have a 3.6 times greater risk of GDM as compared to normal 
weight controls (Roberts and Lain 2002). Similarly, Schrauwers and Dekker (2009) 
showed that overweight, obese, and morbidly obese women in gestation have a 6%, 8%, 
and 21.7% chance, respectively, of developing GDM as opposed to 1% for normal 
weight women. GDM is usually determined by an oral glucose tolerance test at week 24 
of gestation, but in obese women, the condition can arise much sooner than that, and so 
the condition remains unrecognized until it is too late for optimal management (Galtier 
et al. 2004). GDM also predisposes a woman for type II diabetes mellitus later in life, 
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and so proper therapy should be initiated as soon as possible to prevent future health 
risks associated with GDM.   
 Excess weight also increases the prevalence of hypertension and toxemic 
syndromes during pregnancy (Galtier et al. 2008). In obese women, the incidence of 
hypertension is increased by a factor of 2.2-21. Bhattacharya et al. (2007) found a linear 
increase in gestational hypertension with BMI, as well as an adjusted odds ratio of 3.1 
for gestational hypertension in the morbidly obese. Gestational hypertension may be the 
result of decreased nitric oxide (a vasodilator) synthesis, and obesity also lessens 
synthesis of this molecule (Poirier et al. 2006), which can lead to endothelial dysfunction 
and future cardiovascular disease.  
  Obesity, insulin resistance (such as in the form of GDM), and 
hypertriglyceridemia, along with endothelial dysfunction as a result of decreased nitric 
oxide synthesis are all important factors for the pathogenesis of preeclampsia 
(Ramachenderan et al. 2008). Endothelial dysfunction reduces prostacyclin secretion and 
enhances peroxidase production that results in vasoconstriction and platelet aggregation. 
Indeed, obesity has been identified as an independent and well-established risk factor for 
the development of preeclampsia (Roberts and Lain 2002; O’Brien et al. 2003; Eskenazi 
et al. 1991). Preeclampsia is a rapidly progressing condition that is manifested in 
maternal hypertension and proteinuria, and can result in coma or death of the mother.  It 
is one of the major contributors to maternal morbidity and mortality worldwide, and has 
been associated with substantial health concerns later in life (WHO 2009). Large 
population studies have shown that obese women are two to three times more likely to 
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develop preeclampsia than women of normal body weight (O’Brien et al. 2003; Baeten 
et al. 2001). Another study also confirmed that increasing BMI results in an odds ratio of 
7.2 for developing preeclampsia as opposed to normal BMI women (Bhattacharya et al. 
2007). Even in studies in which women with GDM are excluded, obesity is still an 
independent risk factor for preeclampsia (Jensen et al. 2003).  
 Pregnancy is a hypercoagulable state, associated with increases in the plasma 
concentrations of coagulation factors, decreases in protein S (a plasma glycoprotein 
involved in anti-coagulation pathways), and inhibition of fibrinolysis, resulting in a 5-
fold increase in risk for venous thrombosis (Hellgren and Blomback 1994; Greer 1994). 
Obesity further increases the risk of thrombosis events by promoting venous stasis, 
increasing blood viscosity, and promoting activation of the coagulation cascade 
(Ramachenderan et al. 2008). Since obesity is characterized by an excess of adipose 
tissue, any chemical mediators produced by this tissue is elevated, which puts anyone at 
risk for complications. Adipose tissue has been found to secrete numerous “adipokines”, 
tumor necrosis factor alpha (TNFA), interleukin-6 (IL6), leptin, and others (Ikeoka et al. 
2010). These peptides and non-peptide compounds, which can be involved in 
cardiovascular homeostasis, can slow clot degradation and result in a furthered 
prothrombic state. This can place obese pregnant women at an increased risk for 
developing deep vein thrombosis, blood clots, and other thromboembolic complications.  
 Also of interest is the occurrence of respiratory complications in obese pregnant 
women. Excess weight causes a reduction in thoracic-wall compliance and increases 
airway resistance (Galtier et al. 2008). Sleep-disordered breathing and snoring are fairly 
  
10
common in pregnancy, and women with higher BMIs and increasing neck circumference 
during pregnancy report higher sleep apnea scores (Pien et al 2005).  
 Obesity in pregnancy can result in numerous delivery complications. It could be 
argued that these women have higher incidences of delivery complications due to 
underlying medical conditions associated with their weight. However, Callaway et al. 
(2006) found that associations between increasing BMI and poor delivery outcomes 
were still present after adjustment for the presence of other conditions such as GDM. 
Several studies have evaluated the effect of obesity on preterm delivery, and most have 
concluded that the risk of preterm birth is not increased (Ramachenderan et al. 2008). 
One study even found that the risk actually decreases in obese versus normal weight 
women (6.2% and 11.2%, respectively) (Hendler et al. 2005). However, obese women 
are more likely than overweight and normal weight women to progress beyond term, but 
the increased difficulty in determining start of gestation in these women may mean that 
the phenomenon is an artefactual association (Ramachenderan et al. 2008). Obese 
women have a higher rate of induced labor and more cesarean sections than normal 
weight women. Indeed, Bhattacharya et al. (2007) reported that the frequency of induced 
labor increased with rising BMI, such that a normal weight woman had an odds ratio of 
0.8, while obese women were at 1.8. Further, both elective and emergency cesarean 
sections were increased in the morbidly obese group, but only emergency surgeries were 
significantly different from other BMI categories. Another study found that around one 
in two severely obese women were delivered by cesarean section and each one-unit 
increase in pregravid BMI increased the risk of a surgical delivery by 7% (Brost et al. 
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1997). Commonly reported reasons for surgical delivery included cephalopelvic 
disproportion, failed cervical dilatation, fetal distress, and risk of shoulder dystocia. 
Additionally, obesity in pregnancy is associated with more difficulties with anesthetic 
administration. Difficulties in inserting epidural catheters include correct positioning of 
the patient, midline and epidural space identification, and dislodging the catheter (Galtier 
et al. 2008). However, regional anesthesia seems to be the preference for obese women, 
as intubation of these women can be difficult, and a rapid desaturation and an increased 
risk of aspiration is associated with obese women during anesthesia (Saravanakumar et 
al. 2006). Obese women are also at greater risk for deep vein thrombosis, endometritis, 
postpartum hemorrhage, wound infections, urinary tract infections, and prolonged 
hospitalization associated with delivery complications (Hall and Neubert 2005). Indeed, 
Bhattacharya et al (2007) found that mean blood loss following delivery showed a linear 
increase with increasing BMI.  
 Finally, there are a host of postpartum issues that overweight and obese mothers 
could encounter. Excess weight gain during pregnancy and high prepregnancy weight 
are important predictors of long-term weight change and higher BMI later in life 
(Ramachenderan et al. 2008; Gore et al. 2003). Scholl et al. (1995) found that excess 
gestational weight gain resulted in a 12% increase in weight from prepregnancy at 6 
months postpartum, and retained approximately 40% of that excess weight. This is in 
comparison to women who gained the recommended weight, who tended to weigh only 
5% more than prepregnancy weight postpartum. This relates to obesity in pregnancy 
because excessive weight gainers are more likely to have been overweight or obese prior 
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to pregnancy. Further, women who have higher prepregnancy weights are at risk for 
substantial postpartum weight retention. Soltani and Fraser (2000) found that the 
majority of obese women were heavier 6 months postpartum than they were early in 
their pregnancy. Retaining this excess weight places these women at greater risks of 
further complications with future pregnancies, as well as higher risks for cardiovascular 
disease, type II diabetes, atherosclerosis, and the metabolic syndrome. 
Fetal and neonatal complications 
Obesity during pregnancy can also give rise to disease and complications in the 
offspring. Maternal obesity has been associated with markers of fetal distress, stillbirths, 
and neonatal deaths (Shaikh et al. 2009). Higher BMI categories have been associated 
with an increased odds ratio of meconium aspiration, fetal distress, and low Apgar score 
(Cedergren 2004). Further, the CEMACH 2006 dataset indicated that of the women who 
had a stillbirth or neonatal death and had a recorded BMI, 26% were overweight and 
22% were obese (Confidential Enquiry into Maternal and Child Health 2008). Therefore, 
almost one half of the stillbirth/neonatal deaths were associated with excess maternal 
weight. Indeed, Huang et al. (2000) found that the factor most closely associated with 
unexplained fetal death was increased prepregnancy weight. Consistent with this finding 
is the fact that obesity was associated with a five-fold increase in the rate of stillbirths 
with histological placental dysfunction in the 1998-2001 Danish National Birth Cohort 
(Nohr et al. 2005). The mechanism of fetal compromise has not been determined and 
likely involves a plethora of factors, including placental insufficiency, relative fetal 
hypoxia, and the dysfunction of fetal organs (Sebire et al. 2001).  
  
13
 Maternal obesity is a well-recognized risk factor for fetal macrosomia: birth 
weights greater than 4 kg. Certainly, multiple studies have shown strong associations 
between maternal obesity and macrosomia (Sebire et al. 2001; Baeten et al. 2001; Jensen 
et al. 2003). In agreement, Bhattacharya et al. (2007) found that macrosomia was more 
common in obese and morbidly obese groups with odds ratios of 1.9 and 2.1, 
respectively. Macrosomia can also cause its own set of complications. Fetal overgrowth 
brings about an increased risk of shoulder dystocia, birth injury, and neonatal death, 
which can further lead to delivery complications in the mother and an increased risk of 
perineal trauma, chorioamnionitis, or postpartum hemorrhage (Stotland et al. 2004).  The 
mechanism by which obesity affects neonatal birth weight is unclear. However, it is 
thought to include obesity-related insulin resistance, in which the elevated insulin levels 
signal for rapid fetal growth, and genetic factors (Yogev and Catalano 2009). With the 
recent interest in the field of epigenetics and the developmental origins of health and 
disease hypothesis (Barker Hypothesis), much more knowledge will be learned as to the 
genetic mechanisms of how obesity affects fetal growth (reviewed in Satterfield et al. 
2010). 
 Maternal obesity is also a risk factor for congenital abnormalities, because 
obesity during pregnancy can affect embryogenesis (Galtier-Dereure et al. 2000; 
Ramachenderan et al. 2008). Data from the National Institute of Neurological and 
Communicative Disorders and Stroke showed an increase of major congenital 
abnormalities of 35% when mothers were overweight and 37.5% when obese (Naeye 
1990). The most common abnormality is neural tube defects, specifically spina bifida. 
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Odds ratios for neural tube defects range from 1.8 to 3 depending on the degree of 
maternal overweight (Galtier-Dereure et al. 2000). Due to the fact that neural tube 
defects are typically associated with a suboptimal folic acid intake by the mother, it has 
been speculated that there is potentially a decrease in the absorption of folic acid from 
the diet in obese women. However, this suggestion has been met with inconsistent study 
results (Yogev and Catalano 2009). Other birth defects have also been associated with 
maternal obesity, such as a doubling of the risk for omphalocele and heart defects 
(Watkins et al. 2003), an increase in cryptochidism in male infants, and elevated risk of 
fluctuating dental asymmetry indicating developmental destabilization (Berkowitz et al. 
1995; Kieser et al. 1997). Related is the fact that there is an increased chance of failure 
to detect birth defects in obese women because of difficult interpretation of serum 
markers due to changes in the volume of distribution, as well as suboptimal visualization 
of fetal anatomy by ultrasound. Indeed, Hendler et al. (2004) found that the rate of 
suboptimal visualization of fetal cardiac and craniofacial structures increased by 37% 
and 43% in obese women, respectively. Similar studies have shown that these affected 
structures include the heart, umbilical cord and spine, which are all known sites of 
obesity related deformities (Wolfe et al. 1990).   
Obesity management during pregnancy 
Previous recommendations regarding weight loss during pregnancy have been 
unfavorable. In fact, many experts believe that losing weight during pregnancy is always 
inadvisable (Galtier et al. 2008), no matter the degree of obesity. However, a 2007 study 
regarding gestational weight gain during pregnancy showed minimal risks of 
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unfavorable pregnancy outcomes in greatly obese women losing 0-9 pounds (Kiel et al. 
2007). Further, Artal et al. (2007) found that birth weights were more likely to be in the 
normal range among infants born to women who either lost weight or did not gain 
weight from the time of an obesity intervention to delivery, along with a lower 
percentage of small and large for gestational age infants. Therefore, although it may be 
beneficial to all that obese women consider losing weight before becoming pregnant, the 
means of obesity management (caloric restriction, exercise, etc.) during gestation could 
improve maternal health and not significantly impair growth and development of the 
fetus.  
 The current literature is sparse on reports of studies regarding forms of obesity 
management during pregnancy on long-term maternal and fetal outcomes. Maternal 
weight gain has been significantly associated with caloric intake, and therefore caloric 
restriction could be used to decrease weight gain during pregnancy. Severe caloric 
restriction (> 50% calorie restriction) has been found to increase ketonuria and 
ketonemia in pregnant women, and these can lead to impaired mental development in the 
fetus. However, a 33% reduction in caloric intake has been recommended to control 
weight gain while not leading to ketosis.  Furthermore, it seems that caloric restriction 
would be less harmful in obese women, because gestational weight gain appears to 
benefit maternal fat stores rather than birth weight in obese women (Luke et al. 1996). 
Another potential strategy to reduce weight gain and/or induce weight loss during 
gestation is moderate aerobic exercise. Exercise has been noted to be an effective 
treatment option in improving outcome of pregnancy. Further, there are reports that 
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exercise has no effect on birth weight and that vigorous exercise may even result in a 
reduction in birth weight by up to 400 grams (Gavard and Artal 2008). Measures of 
physical activity have been observed to be reduced during pregnancy, possibly due to the 
belief that all forms of exercise in pregnancy are contraindicated; however, exercise has 
been determined to be safe in pregnancy for both maternal and fetal well-being (Shaikh 
et al. 2009). One factor that may have implications in fetal outcome may be the type of 
exercise performed. The risk of uterine contractions (and thereby adverse effects on the 
fetus) may be increased by lower-extremity exercise, whereas upper body exercise 
produces no uterine contractions (Jovanovic-Peterson and Peterson 1991).  Going 
against long-held beliefs, it seems that neither moderate caloric restriction nor an 
increase in physical activity has a negative impact on fetal health, and can greatly benefit 
maternal well-being both during and after pregnancy.  
 One final obesity management method that is of possible benefit is the use of 
pharmaceuticals or nutraceuticals as a means to reduce weight. One enzyme that has 
emerged as a potential target for dissipation of adipose tissue is AMP-activated protein 
kinase (AMPK). AMPK is considered a master switch, regulating key proteins in 
metabolic pathways known to control fatty acid and glucose oxidation in the liver and 
skeletal muscle, as well as lipolysis in adipocytes (Winder and Hardie 1999). Since 
skeletal muscle and adipose tissue are the main sites of energy utilization, finding ways 
to modulate AMPK activity in these tissues may play a significant role in energy 
homeostasis and lead to depletion of fat stores. One such method is through the use of 
the experimental drug 5-aminoimidazole-4-carboxamide-1--D-riboruranoside, also 
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known as AICAR. AICAR is an adenosine analogue that can be absorbed into intact 
hepatocytes, adipocytes, and skeletal muscle, and once phosphorylated, mimics the 
effects of AMP on AMPK, thereby activating this regulatory protein (Song et al. 2002). 
AICAR has been used in numerous studies involving diet-induced obese mice, 
genetically obese mice, diabetic rats, and cell culture studies (Hardie et al. 2003). 
Overall, available  evidence indicates  that chronic AICAR administration causes a 
strong anti-lipogenic effect by increasing expression of key inhibiting factors of 
adipocytes differentiation such as peroxisome proliferator-activated receptor alpha and 
gamma (PPAR and PPAR), and PPAR coactivator 1-alpha (PGC-1). Further, 
AICAR suppressed fatty acid uptake and promoted fatty acid oxidation in white adipose 
tissue (Gaidhu et al. 2009).  This provides novel evidence that AICAR, through AMPK 
activation, can remodel white adipose tissue and other insulin-sensitive tissues to 
increase oxidation of energy substrates. One negative effect observed, however, is the 
alteration of the blood lipid profile in both normal and genetically obese mice. Song et 
al. (2002) found that plasma levels of non-esterified fatty acids (NEFA) were increased 
in rats, probably attributable to increased lipolysis in adipocytes. Regarding AICAR 
administration as a whole, tissue-specific and pathway-specific strategies involving 
AMPK must be developed to support the beneficial effects of AICAR while minimizing 
the adverse effects on the blood lipid profile.  
Instead of using drugs, nutrients, particularly amino acids, may play a significant 
role in prevention and treatment of obese subjects during pregnancy (McKnight et al. 
2010).  As precursors for the synthesis of physiologically important substances, amino 
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acids have versatile roles in the maintenance of whole-body homeostasis (Wu 2009).  Of 
particular interest, L-arginine, L-cysteine, and glycine are substrates for the generation 
of NO, CO, and H2S (gaseous signaling molecules) in cells, respectively (Li et al. 2009; 
Tan et al. 2009b).  Because obese or diabetic subjects often have vascular dysfunction 
(Wu and Meininger 2009), modulating the arginine-NO (a major vasodilator) pathway 
may be a promising therapeutic means for the management of overweight or obese 
women before and during pregnancy, as previously demonstrated for nonpregnant 
mammals (Wu et al. 2006; 2009). Notably, dietary supplementation with L-arginine 
reduces obesity in Zucker diabetic fatty rats (a Type-2 diabetic animal model) (Fu et al. 
2005; Wu et al. 2007b), diet-induced obese rats (Jobgen et al. 2009a; Jobgen et al. 
2009b), growing-finishing pigs (He et al. 2009; Tan et al. 2009a,b), and obese humans 
with Type-2 diabetes (Lucotti et al. 2006). Besides increasing cAMP concentrations 
(McKnight et al. 2010) and activating the mTOR signaling pathway (Rhoads and Wu 
2009; Tan et al. 2010; Yao et al. 2008) in insulin-sensitive tissues, L-arginine acts in 
many of the same ways as AICAR, such as increasing the activities of AMPK and other 
proteins that stimulate fat and glucose metabolism (Fu et al. 2005; Nall et al. 2009; Tan 
et al. 2010). Additionally, Jobgen et al. (2009b) found that high fat feeding altered gene 
expression in white adipose tissue of adult rats, including decreases in mRNA levels for 
AMPK and antioxidative proteins, whereas arginine supplementation attenuated these 
adverse affects.  Enteral or parenteral administration of L-arginine or its immediate 
precursor (L-citrulline) is safe and effective in increasing circulating levels of arginine in 
both the mother and the fetus (Lassala et al. 2009; Mateo et al. 2007; Wu et al. 2007a).  
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Therefore, supplementation with L-arginine or L-citrulline could result in beneficial 
effects on improving pregnancy outcomes in overweight or obese mammals (including 
women, pigs, sheep, and rats).  Future research is warranted to test this novel hypothesis. 
Summary and objectives  
In summary, the current obesity epidemic is a major public health problem worldwide, 
which adversely affects an increasing number of pregnant women.  Growing evidence 
shows that maternal obesity negatively impacts maternal health during gestation as well 
as fetal growth and development and postnatal metabolism and health in offspring.  
However, little is known about effects of obesity before and during gestation on both the 
short- and long-term postpartum health of mothers. This study utilized an ovine model of 
obesity to focus on the following objectives: 
1. Evaluate the effects of maternal obesity on amino acid and glucose metabolism 
in ewes at parturition; 
2. Assess the long-term implications of maternal obesity on amino acid and 
glucose metabolism in postpartum ewes; 
3. Determine the effects of postpartum obesity management on amino acid and 
glucose metabolism in ewes; and  
4. Evaluate the effects of obesity management during pregnancy and after 
parturition on amino acid and glucose metabolism in ewes.  
Hypothesis 
Our hypothesis was that gestational obesity would negatively impact amino acid and 
glucose metabolism in ewes, and that obesity management during pregnancy and/or after 
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parturition would ameliorate abnormalities of amino acid and glucose metabolism in 
previously obese ewes. 
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CHAPTER II 
IMPACTS OF MATERNAL OBESITY ON METABOLIC PROFILES IN 
POSTPARTUM EWES 
 
Obesity is a major health problem for both adults and children worldwide (Bray and 
Bellanger 2006; CDC 2009). Particularly, obesity during pregnancy can lead to major 
complications for both the mother and fetus, including gestational diabetes, hypertensive 
disorders of pregnancy, delivery complications, and congenital abnormalities (Galtier et 
al. 2008; Galtier-Dereure et al. 2000; Shaikh et al. 2009).  This is a serious concern for 
healthcare specialists, because 1 in 5 women are obese at the start of pregnancy and 
approximately  65% of women of reproductive age are overweight or obese (CDC 
2009). The best way to avoid these adverse effects of maternal obesity is to reduce body 
weight before pregnancy. However, this is often not practical as many women enter into 
pregnancy unknowingly, thereby necessitating treatment and action during gestation to 
minimize obesity-associated complications (Catalano 2007).  
 Growing interest in the field of epigenetics, fetal programming, and the 
developmental origins of health and disease (DOHaD) hypothesis have led to numerous 
studies to define how gestational obesity affects metabolic programming and 
development of the neonate (Galtier-Dereure et al. 2000; Shaikh et al. 2009; Barker and 
Osmond 1986; Yogev and Catalano 2009; Ramachenderan et al. 2008). However, there 
has been limited research on maternal effects of obesity during or after parturition, while 
the health and well-being of the mother is also an important matter.  We hypothesized 
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that maternal obesity would have both short- and long-term impacts on insulin 
sensitivity in the mother and that reducing obesity during pregnancy or after parturition 
can ameliorate this metabolic problem. This hypothesis was tested in the current study 
using the pregnant ewe (Ovis aries), a widely used animal model for human pregnancy 
(Barry and Anthony 2008).  
Materials and methods 
All surgical and experimental procedures were in compliance with the Guide for the 
Care and Use of Agricultural Animals in Research and Teaching and approved by the 
Institutional Animal Care and Use Committee of Texas A&M University. 
Experimental design 
The experimental design is illustrated in Figure 1. At 120 days prior to estrus, 
multiparous Suffolk ewes were assigned randomly to either receive 100% of National 
Research Council (NRC) nutrient requirements (Control group, n=8) or have free access 
to feed (obesity induction; three groups of obese ewes; n = 8/group).  After 120 days on 
the feeding regimens, control-fed and obese ewes were synchronized into estrus and a 
single blastocyst from a super-ovulated Suffolk ewe of normal body condition score was 
transferred into the uterus on day 6 post-estrus. Pregnancy was confirmed by ultrasound 
on day 28 of gestation.  Ewes in the control group were maintained on 100% NRC 
feeding throughout gestation. Beginning on day 42 of gestation (36 days after embryo 
transfer), one group of obese ewes were restricted to 65% of NRC nutrient requirements 
(OB-NR) and the remaining two groups of obese ewes continued to have free access to 
feed throughout gestation.  Following parturition, the control and one obese group 
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continued to be fed 100% NRC nutrient requirements and to have free access to feed, 
respectively, whereas the other obese group and OB-NR groups were realimented to 
100% NRC nutrient requirements (OB-RAL and OB-NR-RAL, respectively).  Two ewes 
in the obese group died within 1 mo after parturition, and only 6 ewes remained in this 
group for subsequent measurements.  During pregnancy and after parturition, all ewes 
were individually fed and weighed weekly, whereas feed intake for control-fed and OB-
NR fed ewes was adjusted based on body frame size. 
 
 
Figure 1 Experimental Design.  At 120 days prior to estrus, ewes were assigned 
randomly to either receive 100% of NRC nutrient requirements (n = 8) or have free 
access to feed (obesity induction; three groups of obese ewes; n = 8/group).  After 120 
days on the feeding regimens, ewes received the transfer of single blastocysts from a 
super-ovulated ewe on day 6 post-estrus. Beginning on day 42 of gestation, one group of 
obese ewes were restricted to 65% of NRC nutrient requirements (OB-NR) and the 
remaining two groups of obese ewes continued to have free access to feed throughout 
gestation.  Following parturition, the control and one obese group continued to be fed 
100% NRC nutrient requirements and to have free access to feed, respectively, whereas 
the other obese group and OB-NR groups were realimented to 100% NRC nutrient 
requirements (OB-RAL and OB-NR-RAL, respectively).   
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Glucose Tolerance Test (GTT) 
On postpartum day 1 (PPD1) and postpartum day 150 (PPD150), following a 12 
h fast, a glucose tolerance test was administered to ewes by i.v. infusion of a 50%  
glucose solution (0.25 mg/kg body weight) (Ford et al. 2007). Blood samples were 
obtained from the jugular vein in 3 mL EDTA-K2 tubes (BD Vacutainer) at 0, 5, 10, 15, 
30, 60, 120, and 180 min after the bolus injection of glucose solution. Blood samples 
were immediately centrifuged at 3,500 x g for 5 min to obtain plasma which was 
aliquoted into 1.5 mL tubes and stored at -20° C until analyzed.  
Biochemical analyses of plasma from ewes 
Concentrations of leptin in plasma were determined as described by Delavaud et 
al. (2000). Concentrations of insulin in plasma were measured by EIA (Catalog number 
80-INSOV-E01, ALPCO Diagnostics) according to manufacturer’s recommendations. 
Non-esterified fatty acids (NEFA) were determined using a commercial colorimetric 
assay (Wako Chemicals, Richmond, VA). Amino acids, glucose, ammonia, and urea in 
plasma were analyzed using HPLC and enzymatic methods (Wu et al. 1997; Kohli et al. 
2004; Wu 1995; Wu et al. 1995).  
Statistical analysis 
Values are least square means and pooled SE.  Data were analyzed by ANOVA 
using the General Linear Model procedures of the Statistical Analysis System (SAS 
Institute, Inc.). Leptin was analyzed by 1-way ANOVA, while all others were analyzed 
by 2-way ANOVA with diet and time being main effects. Values of P  0.05 were taken 
to indicate statistical significance.  
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Results 
Body weights of ewes on PPD1 and PPD150 
On PPD1, body weights of control, obese, and OB-NR ewes were 80.0, 116, and 
86.4 kg (pooled SEM = 3.75 kg), respectively.  Obese ewes were 45% and 34% heavier 
(P < 0.01) than control and OB-NR ewes, respectively.   On PPD150, body weights of 
control, obese, OB-RAL, and OB-NR-RAL ewes were 70, 117, 98, and 80 kg (pooled 
SEM = 4.1 kg), respectively (P < 0.0001).   Body weights of ewes differed (P < 0.05) 
among the obese, OB-RAL, and OB-NR-RAL groups, whereas no difference was 
detected between the control and OB-NR-RAL groups.     
Concentrations of leptin in plasma 
On PPD1, concentrations of leptin in plasma were greater in both OB-NR (P < 
0.05) and obese (P < 0.01) ewes than in control-fed ewes (Table 1). On PPD150, plasma 
leptin levels in OB-RAL and obese ewes were elevated (P < 0.05 and P < 0.01, 
respectively) in comparison to the control group, but values for OB-NR-RAL and 
control ewes did not differ (Table 1). Additionally, obese ewes had a 79% increase (P < 
0.05) in concentrations of leptin in plasma over values in OB-RAL ewes. 
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Table 1 Concentrations of leptin, ammonia, urea, and non-esterified fatty acids (NEFA) 
in plasma of ewes on PPD1 and PPD1501 
 
Group n Leptin Ammonia Urea NEFA 
     µg/L µmol/L mmol/L mmol/L 
 
PPD1 
 
 Control 8 4.2c 126 5.0 0.36c 
 Obese 16 19.4a 156 6.6 0.63a 
 OB-NR 8   8.9b 141 5.6 0.49b 
 
 SEM  1.5     7.2 0.35 0.03 
 P-Value  <0.01     0.25 0.21 <0.05 
 
PPD150 
 
 Control 8     4.7c 142a 4.3b 0.20c 
 Obese 6 26.2a   79b 5.6a 0.57a 
 OB-RAL 8 14.6b 109ab 4.2b 0.38b 
 OB-NR-RAL 8     8.6bc 104b 4.6b 0.23c 
 
  SEM    1.4   6.0 0.13 0.02 
  P-Value   <0.01  <0.01     <0.01 <0.01 
 
1Values are means with pooled SEM. Means within a column without a common letter 
differ, P < 0.05. 
 
 
 
Concentrations of insulin in plasma 
On PPD1, concentrations of insulin in plasma differed (P < 0.01) due to time and 
treatment after i.v. administration of glucose solution (Table 2).  Baseline concentrations 
of insulin in plasma did not differ among treatment groups. Peak concentrations of 
insulin occurred at 10 min for control-fed and obese ewes and at 30 min for OB-NR 
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ewes. Circulating levels of insulin returned to baseline values by 30 min for control-fed 
ewes and by 120 min for obese and OB-NR ewes.   
On PPD150, there were effects of both treatment and time on concentrations of 
insulin inn plasma (P < 0.01), but their interaction was not significant (Table 2). 
Baseline concentrations of insulin in plasma did not differ among treatment groups. In 
both control-fed and OB-RAL ewes, concentrations of insulin in plasma peaked at 10 
min.  However, circulating levels of insulin returned to baseline by 60 min for control-
fed ewes and 120 min for OB-RAL ewes.  In contrast, concentrations of insulin in 
plasma of obese and OB-NR-RAL ewes peaked at 30 min and returned to basal levels by 
60 and 120 min, respectively.  OB-RAL ewes had higher (P < 0.01) concentrations of 
insulin in plasma at 10 min compared with all other groups and at 30 min, compared 
with control-fed and OB-NR-RAL ewes. Concentrations of insulin in plasma of obese 
ewes remained higher (P < 0.01) than all other groups at 120 min post administration of 
glucose solution. 
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Table 2 Concentrations of insulin in plasma of ewes on PPD1 and PPD1501 
 
Group n Time after i.v. administration of glucose (min) 
   ______________________________________ 
   0 5  10 30 60 120 
        ng/mL 
 
PPD1 
 
 Control 8 0.8 1.8a 2.2a 1.6a 1.9a 1.1a 
 Obese 16 0.6 1.6a 2.4a 1.8a 1.8a 0.7ab 
 OB-NR 8   0.4 1.1b 1.0b 1.1b 1.2b 0.6b 
 
 SEM  0.02 0.02 0.03 0.03 0.02 0.02 
 P-Value  0.48 <0.05 <0.01 <0.05 <0.05 <0.05  
 
PPD150 
 
 Control 8   0.3c 1.2b 1.8b 1.7b 0.7c 0.3b 
 Obese 6 1.0a 2.1b 2.1b 2.1b 2.1a 1.7a 
 OB-RAL 8 0.7ab 2.3a 3.1a 3.0a 1.7ab 0.6b  
 OB-NR-RAL 8   0.5bc 1.6ab 1.7b 2.1b 1.2bc 0.3b   
 
  SEM  0.01 0.02 0.02 0.01 0.02 0.01    
  P-Value  <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
 
1Values are means with pooled SEM. Means within a column without a common letter 
differ, P < 0.05. 
 
   
Concentrations of ammonia, urea, and non-esterified fatty acids in plasma 
On PPD1 and PPD150, there were no effects of time for either levels of ammonia 
or urea in plasma; therefore, data were pooled across time for analysis by ANOVA.  On 
PPD1, concentrations of ammonia and urea in plasma were not different among the three 
groups of ewes (Control, Obese, and OB-NR), but circulating levels of NEFA were 
affected (P < 0.05) by dietary treatment (Table 1). Obese ewes had higher (P < 0.05) 
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levels of NEFA in plasma than control-fed ewes, and OB-NR ewes had intermediate 
levels of circulating NEFA.   
On PPD150, concentrations of ammonia and urea in plasma were affected by 
dietary treatment (Table 1).  Obese and OB-NR-RAL ewes had lower (P < 0.05) levels 
of ammonia in plasma than control-fed ewes, but values for OB-RAL ewes did not differ 
from other treatments. Obese ewes had higher (P < 0.05) concentrations of urea in 
plasma than control, OB-NR-RAL, and OB-RAL ewes. An effect of treatment was 
detected (P < 0.01) for concentrations of NEFA in plasma (Table 1). In particular, obese 
ewes had higher (P < 0.01) concentrations of NEFA in plasma than OB-RAL, OB-NR-
RAL, and control-fed ewes. Further, OB-RAL ewes had higher (P < 0.05) levels of 
NEFA than OB-NR-RAL and control-fed ewes. Concentrations of NEFA in plasma did 
not differ between OB-NR-RAL and control-fed ewes. 
Concentrations of glucose in plasma  
Whole-body utilization of glucose, indicated by GTT results, was affected by 
dietary treatments on both PPD1 and PPD150 (Table 3). On PPD1, basal concentrations 
of glucose in plasma did not differ among the three treatment groups. In response to the 
intravenous bolus of glucose, concentrations of glucose in plasma increased to peak 
values at 5 min post-administration for control-fed and OB-NR ewes and at 10 min for 
obese ewes. Between 10 and 30 min post- administration, both OB-NR and obese ewes 
had higher (P < 0.05) concentrations of glucose in plasma than control-fed ewes, with 
the exception of obese ewes at 15 min. Circulating levels of glucose returned to baseline 
values by 60 min for control-fed ewes, but not until 120 min for both OB-NR and obese 
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ewes. The area under the curve (AUC) and half-life (T1/2) were greater (P < 0.05), but 
clearance rate (CL) was lower (P < 0.05) for obese compared to control-fed ewes (Table 
4). Maximum concentrations (Cmax) of glucose in plasma did not differ among treatment 
groups (Table 4).  
On PPD150, basal levels of glucose in plasma did not differ among the four 
groups of ewes, but peak concentrations of glucose  were  at 5 min post-administration 
of glucose for all treatment groups (Table 3).  Concentrations of glucose were higher (P 
< 0.05) in obese, OB-RAL and OB-NR-RAL ewes than in control-fed ewes.  At 10 to 15 
min post administration, obese, OB-RAL, and OB-NR-RAL ewes had higher (P < 0.05) 
concentrations of glucose than control-fed ewes. At 30 min, OB-NR-RAL ewes did not 
differ from control-fed ewes in concentrations of glucose in plasma, and at 60 min, 
neither realimented group differed from control-fed ewes. At 180 min, obese ewes still 
had higher (P < 0.001) concentrations of glucose in plasma than the control group. 
Concentrations of glucose returned to baseline concentrations by 60 min in control-fed 
ewes, 120 min in  OB-NR-RAL and OB-RAL ewes, and 180 min in obese ewes (Table 
3). 
Glucose kinetics were affected by dietary treatments (Table 4).  Area under the 
curve (AUC) for glucose did not differ among control-fed, OB-NR-RAL, and OB-RAL 
ewes, but obese ewes had greater (P < 0.05) values than all other treatment groups. 
Further, the half-life (T1/2) of glucose in plasma was longer (P < 0.05) in obese ewes 
than in all other treatment groups.  In contrast, maximum concentrations (Cmax) were 
greater (P < 0.001) in obese ewes than in control-fed and OB-NR-RAL ewes.  Finally, 
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clearance rate (CL) of glucose in plasma was lower (P < 0.05) in obese compared with 
control-fed ewes.  
 
Table 3 Concentrations of glucose in plasma of ewes on PPD1 and PPD1501 
 
Group n Time after i.v. administration of glucose (min) 
   ___________________(min)_____________________ 
   0 5  10  15 30 60 120 180 
         mmol/L 
 
PPD1 
 
 Control 8 3.8 12.7   9.8b      9.7b 7.6b 5.9 3.9 3.0  
 Obese 16 3.5 13.2 13.7a  10.9b 9.9a 7.0 4.7 3.5 
 OB-NR 8   3.7 13.2 12.3a  13.4a 9.9a 7.6 4.4 3.4 
 
 SEM  0.03 0.03 0.03  0.04 0.03 0.04 0.03 0.03 
 P-Value  0.82 0.67 <0.01 <0.01 <0.01 0.16 0.53 0.69 
 
PPD150 
 
 Control 8   2.6 10.3b   9.1b    8.2b 5.9c 3.8b 2.5b 2.5b 
 Obese 6 3.6 12.6a 12.1a  11.3a 9.9a 9.3a 6.1a 4.6a 
 OB-RAL 8 3.1 12.4a 11.1a  10.3a 7.7b 5.2b 3.0b 2.6b  
 OB-NR-RAL 8   2.8 11.9a 10.9a    9.7a 7.2bc 5.0b 3.7b 2.7b  
 
  SEM  0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02    
  P-Value  0.24 <0.05 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
 
1Values are means with pooled SEM. Means within a column without a common letter 
differ, P < 0.05. 
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Table 4  Kinetics of glucose in plasma of ewes on PPD1 and PPD1501 
 
Group n AUC CL Cmax T1/2 
     (min• mL/ mmol/L min 
     mmol)/L (min•kg)  
 
PPD1 
 
 Control 8 1548b 0.93a 9.3 111b  
 Obese 16 2021a 0.74b 9.5 148a 
 OB-NR 8   1479b 0.95a 9.9 100b 
 
 SEM  91 0.04 0.33 6 
 P-Value  <0.05 <0.05 0.70 <0.05 
 
PPD150 
 
 Control 8   1280b 1.63a 6.6c 104b  
 Obese 6 2312a 0.78c 9.5a 167a 
 OB-RAL 8 1235b 1.17b 8.3ab 103b 
 OB-NR-RAL 8   1327b 1.04bc 7.8b 116b 
 
  SEM  127 0.05 0.21 6 
  P-Value  <0.05 <0.01 <0.01 <0.05 
 
1Values are means with pooled SEM. Means within a column without a common letter 
differ, P < 0.05. Abbreviations: AUC- area under the glucose concentration curve; CL- 
clearance rate; Cmax- maximum concentration; T1/2- half-life.
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Table 5 Concentrations of amino acids in plasma of ewes on PPD1 at 0 and 120 min after i.v. administration of glucose1 
  0 min   120 min    P-Value 
 ________________________ ________________________  _________________________ 
 Control Obese OB-NR Control Obese OB-NR SEM Diet Time Diet x Time 
     µmol/L 
Ala 202 192 202 179 206 179 11 0.93 0.63 0.73 
Arg 188 176 163 178 142 127 10 0.30 0.19 0.85 
Asn 26 34 37 22 29 33 2 0.10 0.30 0.99 
Asp 8a 5ab 5ab 6ab 4b 4b 0.5 <0.05 0.18 0.98 
-Ala 20 19 27 26 22 24 2 0.49 0.50 0.55 
Cit 255a 156c 218ab 245ab 141c 219ab 11 <0.01 0.73 0.96 
Cys 82b 169a 97b 72b 145a 91b 8 <0.01 0.42 0.89 
Gln 207b 270a 302a 218b 227b 295a 8 <0.01 0.44 0.36 
Glu 75 94 107 85 102 116 6 0.13 0.47 0.99 
Gly 403c 473b 807a 512b 465b 886a 30 <0.01 0.36 0.71 
His 42b 62a 77a 43b 62a 71a 4 <0.05 0.86 0.92 
Ile 60b 95a 64b 50b 61b 62b 4 <0.05 <0.05 0.19 
Leu 77b 159a 84b 74b 103b 93b 6 <0.01 0.15 0.06 
Lys 94 124 92 106 112 91 7 0.14 0.64 0.47 
Met 19b 24b 20b 46a 27b 23b 2 <0.05 <0.01 <0.01 
Orn 99a 85a 60b 88a 64b 51b 6 <0.05 0.23 0.90 
Phe 49ab 61a 53ab 43b 45ab 47ab 3 0.24 <0.05 0.73 
Pro 87c 116bc 96c 141ab 167a 173a 7 0.22 <0.01 0.72 
Ser 82a 52b 97a 50b 47b 100a 5 <0.01 0.29 0.38 
Tau 46 61 68 52 75 52 5 0.12 0.64 0.66 
Thr 70 87 74 74 102 96 5 0.09 0.34 0.54 
Trp 32a 34a 23b 10c 24b 17bc 2 0.22 <0.01 0.29 
Tyr 66ab 68a 62ab 47b 53ab 52ab 3 0.80 <0.05 0.80 
Val 151b 210a 107c 100c 128bc 110c 9 <0.05 <0.05 0.18 
Total 2357 2662 2681 2449 2425 2491 68 0.52 0.42 0.56 
1Values are means with pooled SEM. Means within a row without a common letter differ, P < 0.05. 
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Table 6 Concentrations of amino acids in plasma of ewes on PPD150 at 0 and 120 min after i.v. administration of glucose1 
 
 
  0 min   120 min          P-Value 
 ______________________________ ______________________________  ________________ 
 Control Obese OB-RAL OB-NR- Control Obese OB-RAL OB-NR- SEM Diet Time Diet x 
    RAL    RAL    Time 
     µmol/L 
Ala 107c 248a 164b 153b 93c 191b 110c 88c 5 <0.01 <0.01 0.28  
Arg 169 227 176 213 199 165 160 169 7 0.56 0.13 0.16 
Asn 26 27 28 35 30 28 23 29 1 0.14 0.36 0.23 
Asp 3 4 4 4 4 5 4 6 0.3 0.16 0.06 0.46 
-Ala 48a 30bc 36ab 45a 20cd 16d 11d 21cd 3 0.45 <0.01 0.86 
Cit 200 208 224 213 179 195 176 202 8 0.87 0.15 0.82 
Cys 88bc 135a 104b 92b 76c 103b 72c 63c 3 <0.01 <0.01 0.72 
Gln 207c 208c 220c 270ab 288ab 294a 239b 311a 7 <0.05 <0.01 0.34  
Glu 42c 74a 70ab 68ab 40c 58abc 46c 52bc 0.4 <0.01 <0.01 0.40 
Gly 311d 378cd 470ab 480ab 427abc 341cd 486ab 506a 19 <0.05 0.43 0.56 
His 110a 71a 100a 107a 47b 33b 37b 47b 5 0.26 <0.01 0.80 
Ile 61ab 71a 69a 57ab 54b 65ab 48b 46b 2 <0.05 <0.01 0.26 
Leu 86ab 110a 87ab 91ab 62bc 84b 46c 56c 3 <0.01 <0.01 0.68 
Lys 78ab 82ab 87ab 96a 74ab 62bc 44c 57c 3 0.59 <0.01 0.15 
Met 17a 19a 18a 19a 15ab 16ab 12b 12b 0.6 0.35 <0.01 0.28 
Orn 109ab 117a 108ab 93ab 84bc 62c 59c 65c 4 0.41 <0.01 0.46 
Phe 45c 66a 57ab 52bc 30de 42cd 28e 28e 1 <0.01 <0.01 0.38  
Pro 134a 71c 141a 131a 112ab 139a 121ab 96bc 4 0.13 0.77 <0.01 
Ser 48c 51c 74b 80a 43c 45c 46c 69b 3 <0.01 0.06 0.60 
Tau 34bc 64a 41bc 44b 31cd 41bc 23d 30cd 2 <0.05 <0.01 0.46 
Thr 125ab 116bc 142ab 161a 90c 87c 98c 83c 9 0.81 <0.05 0.76 
Trp 25c 41a 34ab 33b 35ab 40a 36ab 30bc 1 <0.01 0.48 0.21 
Tyr 64ab 69a 69a 72a 56b 75a 59b 61b 1 <0.01 <0.05 0.08 
Val 140ab 169a 116bc 158a 102c 126b 87c 88c 5 <0.05 <0.01 0.45 
Total 2228abc 2474ab 2542ab 2617a 2174bc 2302abc 2039c 2199bc 49 0.43 <0.01 0.35 
1Values are means with pooled SEM. Means within a row without a common letter differ, P < 0.05. 
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Concentrations of amino acids in plasma 
Concentrations of total amino acids in plasma were unaffected by diet or time on 
PPD1 (Table 5), but there were effects of treatment on specific amino acids. 
Concentrations of histidine increased (P < 0.05) in both obese and OB-NR compared 
with the control-fed ewes, while aspartate and citrulline decreased (P < 0.05 and P < 
0.01, respectively). Concentrations of serine, glutamine, and glycine were greater  (P < 
0.01) in OB-NR ewes, while ornithine levels were lower  (P < 0.05). Circulating levels 
of all branched-chain amino acids (BCAA; isoleucine, leucine and valine) and cysteine 
were also higher (P < 0.05) in obese ewes compared to ewes in the other treatment 
groups.  Time after administration of the glucose tolerance test also had an effect on 
some amino acids, as concentrations of isoleucine, phenylalanine, tryptophan, tyrosine, 
and valine (control-fed and obese ewes) decreased over time (P < 0.05). Only proline 
increased (P < 0.05) after administration of the bolus of glucose.  Concentrations of all 
other amino acids remained unchanged by either diet or time. Of note, methionine levels 
did not differ among treatments or across time, except for control-fed ewes in which 
values were higher at 120 min (P < 0.01).  
On PPD150, concentrations of most amino acids in plasma were affected (P < 
0.05) by either diet or time (Table 6). Concentrations of alanine, glutamate, tyrosine, and 
tryptophan in plasma were higher in obese ewes with or without weight loss compared 
with control-fed ewes (P<0.01). Concentrations of glycine in plasma were greater in 
both realimented groups (OB-NR-RAL and OB-RAL) (P<0.05), but not obese ewes.  
Circulating levels of glutamine (P < 0.05) and serine (P < 0.01) were increased in OB-
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NR-RAL ewes compared to control ewes.  Concentrations of taurine, all BCAA, 
cysteine, and phenylalanine were higher (P < 0.05) in plasma of obese than control-fed 
ewes. Concentrations of glutamine increased (P < 0.05) over time, while alanine, -
alanine, cysteine, glutamine, leucine, phenylalanine, histidine, isoleucine, lysine, 
methionine, ornithine, taurine, threonine, tyrosine, valine, and total amino acids in 
plasma decreased (P < 0.05). Proline concentrations were initially lower in obese ewes, 
but by 120 min after the glucose tolerance test, these ewes had greater levels of proline 
while all other groups exhibited a decrease (P < 0.05, trt x time). Concentrations of 
arginine, asparagine, aspartate, and citrulline did not change (P > 0.05) in response to 
diet or time. 
Discussion 
Obesity during gestation is a common and growing problem around the world (CDC 
2009). Although the literature is vast on fetal implications of maternal obesity during 
pregnancy (Yogev and Catalano 2009; Ford et al. 2007), very little is known about either 
short-term or long-term metabolic impacts of maternal obesity on the mother. The 
present study involved an obese ovine ewe model to elucidate some of the consequences 
of this growing problem in obese gestating women. Obesity was evident in ewes before 
pregnancy to mimic obese women who unknowingly become pregnant. Our results 
indicate that gestational obesity impaired insulin sensitivity on  both PPD1 and PPD150, 
which resulted in a vast amount of downstream adverse effects, including reduced 
utilization of glucose (Tables 3 and 4) as well as altered metabolism of fatty acids (Table 
1) and amino acids (Tables 5 and 6).   
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Obesity can impair the oxidation of fatty acids and glucose (Jobgen et al. 2009a).  
Such an effect, coupled with increased intake of energy substrates (including lipids and 
carbohydrates) from the diet, causes high levels of NEFA (Table 1) in plasma and 
particularly glucose in response to its administration (Table 3).   Long-chain unsaturated 
fatty acids and glucose are known to result in insulin resistance in skeletal muscle and 
other tissues of obese subjects, as reported for type-2 diabetic patients (Marliss et al. 
2006).  An important finding of this work is that reducing body weight (mainly white 
fat) during pregnancy or after parturition improved the metabolic profiles of the ewes. 
Specifically, ewes assigned to obesity management treatments exhibited improvements 
in concentrations of  leptin, NEFA, insulin, and urea in plasma, as well as glucose 
metabolism, in comparison to the obese ewes on both PPD1 and PPD150 (Tables 1 and 
2). Because the ewes were followed for 5 months, the long-term effects of both maternal 
obesity and the management of this condition could be evaluated. To the best of our 
knowledge, this is the first report of effective and safe intervention methods for 
ameliorating the metabolic syndrome in obese mothers.   
Obesity is known to affect protein metabolism (Jobgen et al. 2009b; Marliss et al. 
2006) and gene expression (Jobgen et al. 2009c) in non-pregnant adult animals.  
However, little is known about effects of maternal obesity on this biochemical event in 
the mothers either immediately or in a longer term following parturition.  As an initial 
step to address this question, we determined concentrations of amino acids in ewes on 
PPD1 and PPD150.  As in non-pregnant rats, maternal obesity altered the amino acid 
profile in plasma on both days (Tables 5 and 6).  Of particular note, circulating levels of 
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all BCAA were greater in obese than control-fed ewes.  This suggests impaired 
mitochondrial function in skeletal muscle, the major site for initiation of BCAA 
degradation in mammals (Wu 2009).  In contrast, concentrations of serine and citrulline 
were reduced in the plasma of obese ewes on PPD1 (Table 5), possibly due to reduced 
synthesis from glycine and glutamine, respectively.  In support of this view, 
concentrations of glycine and glutamine were higher in obese than control-fed ewes on 
PPD1 (Table 5).  Altered metabolism of serine and impaired synthesis of citrulline likely 
results in adverse metabolic effects because of the following two reasons.  First, serine is 
a major component of the one-carbon unit metabolism that is essential to cell growth and 
differentiation (Wu 2009).  Second, citrulline is the immediate substrate for intracellular 
synthesis of arginine, which is the precursor of nitric oxide (a major vasodilator, a key 
angiogenic factor, and a gaseous signaling molecule) (Wu et al. 2009).       
Concentrations of urea in plasma can be a good indicator of altered metabolism 
of protein and amino acids in animals, including sheep (Satterfield et al. 2010). In 
keeping with this notion, circulating levels of urea were elevated in obese ewes, but 
reduced in obese ewes that lost weight either during pregnancy or after parturition (Table 
1).  Due to insulin resistance, protein synthesis is reduced, but protein degradation is 
increased in skeletal muscle of obese subjects, resulting in increased amounts of amino 
acids for oxidation and urea formation (Jobgen et al. 2009a).  This metabolic problem is 
diminished in obese mothers when their whole-body insulin action is enhanced through 
weight management, as indicated by reduced concentrations of urea in plasma (Table 1). 
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Obesity along with excess gestational weight gain can negatively impact 
maternal health (Institute of Medicine 1990).  Kiel et al. (2007) reported that 46% of 
obese women gained more than 11.3 kg throughout gestation. Another study found that 
greater than 70% of obese women gained more than the recommended amount of weight 
for obese pregnant women, and 21% gained greater than 16 kg, which would be 
considered excessive even for women of normal pre-pregnancy weight (Vesco et al. 
2009).  Optimal weight loss for obese women during pregnancy remains to be 
established.  In this regard, results of this animal study may have important implications 
for the management of obese pregnant women.   Sheep have similar metabolic profiles to 
humans, and so the findings obtained in this study should be easily translatable to 
conditions in humans (Barry and Anthony 2008; Ford et al. 2007). Furthermore, the 
addition of obesity management treatments either during pregnancy or after parturition 
can give insight into how much the maternal condition can be improved when weight 
loss is induced, a critical subject area not studied in previous research involving maternal 
obesity.  Reducing food intake of obese ewes to 65% of NRC nutrient requirements 
resulted in a desirable weight loss (primarily white fat). Furthermore, our results indicate 
that initiation of weight loss even after parturition was highly beneficial for improving 
the metabolic profile in obese mothers (Tables 1-6).  These results can be helpful in 
recommending weight loss for obese pregnant women.  
 In summary, maternal obesity during gestation led to higher levels of leptin and 
NEFA in plasma, impaired glucose utilization, and an altered amino acid profile.  
Importantly, obesity management during gestation ameliorated these negative effects. 
40 
 
 
Further, continued obesity for long-term periods after parturition can exacerbate the 
problem of high leptin and NEFA levels, which can further impair actions of insulin, as 
well as the metabolism of amino acids, lipids, and glucose in mothers. We conclude that 
obesity management beginning immediately after parturition greatly improved their 
metabolic conditions. These new findings greatly enhance the base of knowledge on 
effects of maternal obesity on the mother and outcomes of dietary interventions for 
successful management of obesity in women during gestation and during the postpartum 
period. 
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CHAPTER III 
SUMMARY AND DIRECTION OF FUTURE RESEARCH 
 
To our knowledge, this study is the first report of safe and effective intervention methods 
for ameliorating the metabolic syndrome in obese mothers. Although weight loss during 
pregnancy has generally been considered unfavorable, the discovery by Kiel et al. (2007) 
that a weight loss of up to 9 pounds can be achieved in obese gestating women with 
minimal risk of an unfavorable pregnancy outcome may lead the way to new 
recommendations regarding gestational weight gain/loss in the obese woman. Results of 
this study could have important implications for the management of obesity in the 
pregnant woman. Because sheep have similar metabolic profiles to humans, our data 
should be easily translatable to clinical medicine.   
The results of this novel study provides a new database for (1) desiging future 
research regarding the effects of maternal obesity on the metabolic syndrome in the 
mother; (2) understanding how excess white fat affects maternal health in the short- and 
long-term periods postpartum; and (3) develop means to minimize/ameliorate these 
negative consequences of this rapidly growing problem.  Therefore, the present work has 
important implications for improving the health and well-being of pregnant women. 
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